Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; PRS 343 (Primary)
  • Indications Bladder cancer; Breast cancer; Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pieris Pharmaceuticals
  • Most Recent Events

    • 11 Nov 2019 According to a Pieris Pharmaceuticals media release, the company will report emerging data from this study at the company's R&D day on November 19th
    • 10 May 2019 According to a Pieris Pharmaceuticals, Inc. media release, data from this study is expected later this year.
    • 07 Nov 2018 According to a Pieris Pharmaceuticals media release, Company intends to report data from this trial in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top